UNSPSC 51141558: Ethadione

This classification denotes an oxazole with the molecular formula C7H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0F8O700BB, chemically known as 2,4-oxazolidinedione, 3-ethyl-5,5-dimethyl- (8ci)(9ci) but generally known as ethadione, which bears US NIH Compound Identifier 10630. European Medicines Agency schedules Ethadione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13728MIG. World Health Organization schedules ethadione in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, ETHADIONE remains the US FDA Preferred Term for this commodity. SMILES: O1C(C(=O)N(CC)C1=O)(C)C.

UNSPSC 51141558 Ethadione is a Commodity code that in recent state and local procurement activity covers naloxone, pharmaceutical products, and drug deactivation systems procured by public health departments, state health agencies, and multistate cooperative purchasing consortia. The code captures what government agencies actually buy under it—emergency response medications, generic pharmaceuticals, over-the-counter products, and harm-reduction supplies—rather than ethadione specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering procurement for multiple states including Oregon). State and local procurement under the code centers on competitive acquisition of pharmaceutical inventories to support community health, emergency response, and benefit programs, with contracts typically structured as fixed-fee or net-pricing arrangements covering multiple years with optional renewal periods.

Recent activity concentrates in Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance reaching across multiple participating jurisdictions. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit managers and group purchasing organizations; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and over-the-counter products distributed across state and local facilities, with awarded contracts effective July 1, 2026, and vendor pricing weighted at 75 percent of evaluation criteria.